The official Kornelia Polyak Lab Twitter account. The Polyak Lab @DanaFarber Cancer Institute is dedicated to the molecular analysis of human breast cancer.
Boston, MA
Joined March 2022
- Tweets41
- Following118
- Followers1.1K
- Likes6
Our study on histone tail cleavage is out today in @NatureGenet . We found KDM4C prevents CTSL-mediated histone H3 tail clipping by modulating its recruiter GRHL2, reducing oxidative stress and promoting basal tumor growth. Congrats to @ZheqiL @nellage
nature.com/articles/s41588-0…
We are thrilled to see our study about ZBTB7A in basal breast cancer is out in @CellReports . We identified ZBTB7A as an novel interactor and regulator of KDM5 using CRISPR screen, and characterized its functional impact on NFkB pathway. Congrats to all!
ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer dlvr.it/TGJSQZ
🎃Polyak lab is getting ready for the MCO halloween pumpkin decoration contest! Huge shoutout to @MarieAnneGoyet1 and Andriana who made this piece of work based on the lab logo! Science and creativity go hand in hand!
We're excited to share that our study on aging has been published today in @Cancer_Cell. We used rat model to identify midkine as a promising driver in breast cancer tumorigenesis. Kudos to all the coauthors especially @yan_pengze !
cell.com/cancer-cell/fulltex…
Thrilled to see our paper on KMT2C/2D in TNBC metastasis is out today in @NatureCellBio. We found loss of KMT2C/2D promotes brain metastasis via KDM6A actviation and MMP3 upregulation. Congrats to our twitterless Marco and all the coauthors!
nature.com/articles/s41556-0…
Our study characterizing breast cancer brain metastasis is officially out in @PNASNews. We reproted breast cancer-stromal cells interaction induces resistance to HER2-targeting agents via bulky glycoproteins. Congrats to @MarieAnneGoyet1 and @nellage.
pnas.org/doi/abs/10.1073/pna…
We are thrilled to announce that Nelly has been elected as a member of the prestigious American Academy of Arts and Sciences. Congratulations! We're so very proud of you!@nellage @DanaFarber @DanaFarberNews
We are pleased to share our Phase II T-DM1+Pertuzumab clinical trial paper is online in @jclinicalinvest today. Tumors w/ or w/o HER2 heterogeneity show distinct modes of response and resistance towards anti-HER2 agents.
jci.org/articles/view/176454
@DFCI_BreastOnc @DanaFarberNews @nellage @ZheqiL @Otto_DFCI @MarieAnneGoyet1 @CarlosArteagaMD @TariKingMD @jenniferbellon2 @DrEricWiner
We are thrilled to see our IBC clinical trial study is officially out in @BCRJournal. We found the use JAK1/2 inhibitor Ruxolitinib in TN-IBC resulted in decreased pSTAT3 but lack of clinical benefits. Comb with immunotherapy may need to be considered.
breast-cancer-research.biome…
Our resource paper on TNBC omic is officially out in @CellReports. We dissected TNBC heterogeneity with deep multiomic profiling on 34 TNBC cell lines and identified drivers of TNBC classification. Congrats to all! @nellage
sciencedirect.com/science/ar…
Our TCR study is officially out today in @PNASNews. Congrats to all the coauthors @simocristea @nellage and #twitterless Jun. We found peripheral blood TCR clonotype diversity is associated with age and intratumor immune in breast cancer patients.
pnas.org/doi/10.1073/pnas.23…
Congrats Nelly for receiving the 2023 #AACR Distinguished Lectureship in Breast Cancer Research Award! We take immense pride in this remarkable achievement, and we remain dedicated to our ongoing efforts in the fight against breast cancer.
Dr. Kornelia P_olyak, a @DanaFarber leading basic and translational scientist in #breastcancer research, is the recipient of the 2023 #AACR Distinguished Lectureship in Breast Cancer Research Award, which will be presented at #SABCS23. @LabPolyak @nellage
aacr.org/about-the-aacr/news…
Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for TNBC is out in @MCT_AACR today. Congrats to all the coauthors! And of course a lot more to be explored in the future. @nellage
aacrjournals.org/mct/article…
